Childhood acute lymphoblastic leukemia

Reviews in Clinical and Experimental Hematology

Volumn 6, Issue 2, 2002, Pages 161-180

  Pui, Ching Hon ^a,b   Relling, Mary V ^c   Campana, Dario ^a   Evans, William E ^c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GLUCOCORTICOID; HYDROCORTISONE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; RASBURICASE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; BIOINFORMATICS; BIOTECHNOLOGY; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DRUG EFFICACY; HUMAN; LEUKEMIA CELL; LEUKEMOGENESIS; MEASUREMENT; MINIMAL RESIDUAL DISEASE; PATHOGENESIS; PHARMACODYNAMICS; PHARMACOGENOMICS; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; SIDE EFFECT; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CHILD; FORECASTING; GENETIC PREDISPOSITION; GENETICS; RISK ASSESSMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM, RESIDUAL; RISK ASSESSMENT;

EID: 0036341504     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-0734.2002.00067.x     Document Type: Review

References (119)

1. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia
2. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
3. Improved outcome for children with acute lymphoblastic leukemia: Results of DanaFarber Consortium Protocol 91-01
4. Acute lymphoblastic leukemia
5. Childhood acute lymphoblastic leukemia - Current status and future perspectives
6. Monoclonal origin of concordant T-cell malignancy in identical twins
7. Protracted and variable latency of acute lymphoblastic leukemia after TEL-AML1 gene fusion in utero
8. Prenatal origin of acute lymphoblastic leukaemia in children
9. High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphblastic leukemia
10. Molecular genetics, natural history and demise of childhood leukaemia
11. Breakage and fusion of the TEL (ETV6) gene in immature B-lymphocytes induced by apoptogenic signals
12. Detection of the TEL-AM1 fusion gene expression in febrile children with virus infections
13. Biological and therapeutic aspects of infant leukemia
14. Topoisomerase II inhibitor-related acute myeloid leukaemia
15. A lack of functional NAD (P) H. quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions
16. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion
17. Methylenetetrahydrofolate reductase (MTHFR) polymorphism and risk of molecularly defined subtypes of childhood acute leukemia
18. The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia
19. Polymorphism in the methylenetetrahydrofolate reductase gene is associated with susceptibility to acute leukemia in adults
20. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia
21. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D 6, GSTM1 and GSTT1 genetic polymorphisms
22. The glutathione S-transferase mu polymorphism and susceptibility to acute lymphocytic leukemia
23. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia
24. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia
25. International childhood acute lymphoblastic leukemia workshop: Sausalito, CA, 30 November - 1 December 2000
26. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
27. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90
28. The Société Française d'Oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia
29. Ethnicity and survival following childhood acute lymphoblastic leukemia (ALL): Follow-up of the Children's Cancer Group (CCG) Cohort
30. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study
31. Outcome of treatment of childhood cancer in black as compared with white children. The St. Jude Children's Research Hospital experience, 1962 through 1992
32. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study
33. Sex differences in prognosis for children with acute lymphoblastic leukemia
34. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986 to 1994
35. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital
36. Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukemia, 1980-97
37. Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group
38. Children's Cancer Group trials in childhood acute lymphoblastic leukemia
39. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
40. Hematologic malignancies with t(4; 11)(q21;q23) - A cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants
41. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia - Implications for treatment of infants
42. Intensified therapy for infants with acute lymphoblastic leukemia: Results from the Dana-Farber Cancer Institute Consortium
43. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 4/89
44. High-risk infant ALL - Improved survival with intensive chemotherapy
45. TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance
46. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia
47. Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup
48. TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification
49. TEL-AML fusion transcript in relapsed childhood acute lymphoblastic leukemia
50. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: Results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol
51. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia
52. TEL/AML1 gene fusion is related to in vitro drug sensitivity for 1-asparaginase in childhood acute lymphoblastic leukemia
53. Origins of 'late' relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes
54. Gene expression signatures define novel oncogenic pathways in T-cell acute lymphoblastic leukemia
55. Pharmacogenomics: Translating functional genomics into rational therapeutics
56. Pharmacogenetics and cancer therapy
57. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy
58. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
59. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia
60. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukemia
61. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus
62. Genetic polymorphism of thiopurine methyl-transferase and its clinical relevance for childhood acute lymphoblastic leukemia
63. High incidence of secondary brain tumours after radiotherapy and antimetabolites
64. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia
65. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: Relation to thiopurine metabolism
66. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study
67. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia
68. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies
69. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia
70. Prevalence of the inactivating 609C→T polymorphism in the NAD (P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
71. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase (letter)
72. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during long-term, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention
73. Pharmacogenetics of methotrexate: Toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism
74. Association of CYP3A4 genotype with treatment-related leukemia
75. Risk assessments in acute lymphoblastic leukemia: Beyond leukemia cell characteristics
76. New definition of remission in childhood acute lymphoblastic leukemia
77. Minimal residual disease in leukaemia patients
78. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia
79. Prognostic significance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia
80. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia
81. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia
82. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia
83. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma
84. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: Results of a compassionate-use trial
85. Meeting report: International childhood ALL workshop, Memphis, TN, 3-4 December 1997
86. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-95
87. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM Study Group from 1981 to 1995
88. Co-operative study of the childhood acute lymphoblastic leukemia (COALL): Long-term follow-up trials 82, 85, 89, and 92
89. Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-91
90. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-95)
91. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: A CLCG-EORTC report
92. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation
93. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-95
94. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
95. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia
96. Double-delayed intensification improves event- free survival for children with intermediate risk acute lymphoblastic leukemia: A report from the Children's Cancer Group
97. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate
98. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study
99. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood
100. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
101. Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia
102. Continuing (maintenance) therapy in lymphoblastic leukeamia: Lessons from MRC UKALL X
103. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine
104. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine
105. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12 000 randomized children
106. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group
107. Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma
108. Bony morbidity in children treated for acute lymphoblastic leukemia
109. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia
110. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St. Jude Children's Research Hospital
111. Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype
112. BFM oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients; results of DCLSG Protocol ALL-8 (1991-96)
113. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone
114. Drug resistance in hematologic malignancies
115. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
116. Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells
117. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
118. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
119. Classification, subtype discovery and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling